{"id":"gw274150","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL114551","moleculeType":"Small molecule","molecularWeight":"219.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GW274150 acts by blocking the action of corticotropin-releasing factor (CRF), a hormone involved in the body's stress response. This leads to a decrease in the production of stress hormones such as cortisol and adrenocorticotropic hormone (ACTH).","oneSentence":"GW274150 is a selective, non-peptide, orally active, small molecule antagonist of the human corticotropin-releasing factor receptor type 1 (CRF1R).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:40:09.356Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT00273013","phase":"PHASE1","title":"Study With GW274150 In Patients With Mild Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-15","conditions":"Asthma","enrollment":28},{"nctId":"NCT00370435","phase":"PHASE2","title":"Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-08","conditions":"Arthritis, Rheumatoid","enrollment":6},{"nctId":"NCT00242866","phase":"PHASE2","title":"Use Of GW274150 In The Prophylactic Treatment Of Migraine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Migraine Disorders","enrollment":430},{"nctId":"NCT00379990","phase":"PHASE2","title":"A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01","conditions":"Arthritis, Rheumatoid","enrollment":48},{"nctId":"NCT00319137","phase":"PHASE2","title":"An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12","conditions":"Migraine Disorders, Migraine","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GW274150","genericName":"GW274150","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GW274150 is a selective, non-peptide, orally active, small molecule antagonist of the human corticotropin-releasing factor receptor type 1 (CRF1R). Used for Treatment-resistant depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}